CNS
MCID: CNT035
MIFTS: 65

Central Nervous System Disease (CNS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Disease

MalaCards integrated aliases for Central Nervous System Disease:

Name: Central Nervous System Disease 12 15 17
Central Nervous System Diseases 45
Cns Diseases 56
Cns Disorder 74
Cns 49

Classifications:



External Ids:

Disease Ontology 12 DOID:331
MeSH 45 D002493
NCIt 51 C2934
SNOMED-CT 69 23853001
ICD10 34 G96 G96.8 G96.9
UMLS 74 C0007682

Summaries for Central Nervous System Disease

Disease Ontology : 12 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary : Central Nervous System Disease, also known as central nervous system diseases, is related to meningitis and neuromyelitis optica, and has symptoms including headache, hemiplegia and hyperexplexia. An important gene associated with Central Nervous System Disease is H19 (H19 Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Neuroscience and IL-17 Family Signaling Pathways. The drugs Ritonavir and Propofol have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are cellular and behavior/neurological

CDC : 3 0 0 0 0

Wikipedia : 77 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...

Related Diseases for Central Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 955)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.9 IFNG IL1B MMP9
2 neuromyelitis optica 32.4 GFAP MBP MOG
3 nervous system disease 32.1 APP BDNF CCR1 CXCR3 GFAP IFNG
4 demyelinating disease 31.4 IFNG IL1B MBP MMP9 MOG PLP1
5 autoimmune disease 31.3 IFNG IL1B MBP MOG
6 alzheimer disease 31.0 APP BDNF GFAP HAR1A IL1B MAPT
7 multiple sclerosis 30.9 BDNF CCR1 CXCR3 GFAP IFNG IL1B
8 panencephalitis, subacute sclerosing 30.9 MAPT MBP MOG
9 dementia 30.8 APP BDNF MAPT TBK1
10 spinal cord injury 30.8 BDNF GFAP MMP9 NOS2
11 acute disseminated encephalomyelitis 30.8 IL1B MBP MOG
12 neuritis 30.7 IFNG IL1B MBP MOG
13 encephalitis 30.7 GFAP IL1B MOG
14 allergic encephalomyelitis 30.6 MBP MOG PLP1
15 hydrocephalus 30.6 APP GFAP MAPT MBP
16 tropical spastic paraparesis 30.6 CXCR3 IFNG MMP9
17 optic neuritis 30.6 MBP MOG PLP1
18 chlamydia 30.6 IFNG IL1B NOS2
19 brain injury 30.5 BDNF GFAP MAPT MBP
20 cerebral amyloid angiopathy, cst3-related 30.5 APP MAPT SERPINA3
21 sarcoidosis 1 30.5 CXCR3 IFNG IL1B
22 amyotrophic lateral sclerosis 1 30.5 APP BDNF GFAP MAPT TBK1
23 traumatic brain injury 30.5 BDNF GFAP MBP
24 prion disease 30.5 APP IL1B MAPT
25 lymphadenitis 30.3 CXCR3 IFNG IL1B
26 relapsing-remitting multiple sclerosis 30.3 BDNF IFNG MBP MMP9 MOG
27 cerebral hemorrhage 30.2 APP GFAP IL1B
28 brain edema 30.1 GFAP IL1B MMP9
29 multiple system atrophy 1 30.1 GFAP MAPT MBP
30 aphasia 30.1 APP BDNF MAPT
31 gliosarcoma 30.1 GFAP IFNG MMP9
32 pediatric cns embryonal cell carcinoma 12.1
33 sjogren-larsson-like ichthyosis without cns or eye involvement 12.0
34 pediatric cns choriocarcinoma 12.0
35 optic atrophy with demyelinating disease of cns 12.0
36 arthrogryposis multiplex congenita cns calcification 12.0
37 ectodermal dysplasia intellectual disability cns malformation 12.0
38 melanocytic lesions of cns 12.0
39 retinopathy anemia cns anomalies 12.0
40 primary melanoma of the central nervous system 11.8
41 mismatch repair cancer syndrome 11.7
42 medulloblastoma 11.7
43 atypical teratoid rhabdoid tumor 11.7
44 cytogenetically normal acute myeloid leukemia 11.7
45 ganglioglioma 11.5
46 cerebral cavernous malformations 11.4
47 superficial siderosis 11.4
48 x-linked charcot-marie-tooth disease 11.4
49 rhabdoid cancer 11.2
50 mannosidosis, alpha b, lysosomal 11.2

Graphical network of the top 20 diseases related to Central Nervous System Disease:



Diseases related to Central Nervous System Disease

Symptoms & Phenotypes for Central Nervous System Disease

UMLS symptoms related to Central Nervous System Disease:


headache, hemiplegia, hyperexplexia

MGI Mouse Phenotypes related to Central Nervous System Disease:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 APP BDNF CCR1 CXCR3 GFAP IFNG
2 behavior/neurological MP:0005386 10.33 APP BDNF GFAP GRM5 IFNG MAPT
3 growth/size/body region MP:0005378 10.32 APP BDNF GFAP GRM5 IFNG IL1B
4 homeostasis/metabolism MP:0005376 10.29 APP BDNF CCR1 CXCR3 GFAP IFNG
5 cardiovascular system MP:0005385 10.28 APP CCR1 CXCR3 GFAP IFNG IL1B
6 hematopoietic system MP:0005397 10.27 APP CCR1 CXCR3 IFNG IL1B MAPT
7 immune system MP:0005387 10.27 APP CCR1 CXCR3 GFAP IFNG IL1B
8 mortality/aging MP:0010768 10.25 APP BDNF CCR1 CXCR3 GFAP IFNG
9 integument MP:0010771 10.09 APP BDNF GRM5 IFNG IL1B MAPT
10 nervous system MP:0003631 10.07 APP BDNF GFAP GRM5 IFNG IL1B
11 muscle MP:0005369 9.97 APP GFAP IFNG MAPT MMP9 MOG
12 neoplasm MP:0002006 9.87 CXCR3 IFNG IL1B MAPT MMP9 NOS2
13 normal MP:0002873 9.76 APP BDNF CXCR3 GFAP IFNG MAPT
14 renal/urinary system MP:0005367 9.5 CCR1 CXCR3 IFNG MAPT MMP9 NOS2
15 vision/eye MP:0005391 9.32 BDNF GFAP IFNG MAPT MBP MMP9

Drugs & Therapeutics for Central Nervous System Disease

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
2
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
3
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Not Applicable 28523-86-6 5206
4
Clobazam Approved, Illicit Phase 4,Phase 3,Not Applicable 22316-47-8 2789
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
9
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 1622-61-3 2802
10
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
11
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 84057-84-1 3878
12
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113775-47-6 5311068 68602
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
14
Levodopa Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-92-7 6047
15
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-65-8 6251 453
16
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 57-27-2 5288826
17
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
19
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
20
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
21
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
22
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
23
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
24
Norepinephrine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-41-2 439260
25
Levomilnacipran Approved, Investigational Phase 4,Not Applicable 96847-54-0
26
Milnacipran Approved, Investigational Phase 4,Not Applicable 92623-85-3 65833
27
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
28
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 51-84-3 187
29
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
31
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
33
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 113-45-1 4158
34
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 134523-00-5 60823
35
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
36
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 73963-72-1 2754
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2 58-93-5 3639
39
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
40
Huperzine A Approved, Experimental Phase 4,Phase 2,Phase 1,Not Applicable 102518-79-6
41
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
42
Candesartan cilexetil Approved Phase 4,Phase 2,Phase 3 145040-37-5 2540
43
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 46783403 6436173
44
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1397-89-3 5280965 14956
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
48
Sodium Citrate Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 68-04-2
49
Lactulose Approved Phase 4,Phase 3,Phase 2,Not Applicable 4618-18-2 11333
50
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
2 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
3 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
4 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
5 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
6 Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy Unknown status NCT01932502 Phase 4 clobazam (Onfi);Initial conversion and titration;Conversion schedule - Week 1;Conversion schedule - Week 2;Conversion schedule - Week 3
7 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
8 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
9 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
10 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
11 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
12 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
13 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
14 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
15 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
16 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
17 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
18 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
19 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
20 A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks Unknown status NCT03159000 Phase 4 Saline
21 Migraine Prophylaxis With Clopidogrel Trial Unknown status NCT02938182 Phase 4 clopidogrel
22 GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
23 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
24 Occipital Transcutaneous Stimulation in Chronic Migraine Unknown status NCT02307071 Phase 4
25 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
26 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
27 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
28 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
29 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4 Induction of anesthesia;Sevoflurane, remifentanil ,vecuronium;Dexmedetomidine;Placebo
30 Methylphenidate for Attention Problems After Pediatric TBI Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
31 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
32 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
33 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
34 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
35 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
36 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
37 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
38 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
39 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
40 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
41 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
42 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
43 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
44 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
45 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
46 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
47 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
48 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Unknown status NCT03077217 Phase 4 Rifaximin
49 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
50 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Genetic Tests for Central Nervous System Disease

Anatomical Context for Central Nervous System Disease

MalaCards organs/tissues related to Central Nervous System Disease:

42
Brain, Spinal Cord, Testes, Bone, Pituitary, Heart, Bone Marrow

Publications for Central Nervous System Disease

Articles related to Central Nervous System Disease:

(show top 50) (show all 463)
# Title Authors Year
1
Adenovirus-Associated Central Nervous System Disease in Children. ( 30413311 )
2019
2
Potential widespread denitrosylation of brain proteins following prolonged restraint: proposed links between stress and central nervous system disease. ( 30414012 )
2019
3
Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. ( 30474195 )
2019
4
Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection. ( 30707437 )
2019
5
Expanding the central nervous system disease spectrum associated with FLNC mutation. ( 30734317 )
2019
6
Immune-Mediated Central Nervous System Disease-Current Knowledge and Recommendations. ( 30808493 )
2019
7
Application of virus targeting nano-carrier drug delivery system in virus-induced central nervous system diseases treatment. ( 31067406 )
2019
8
3D double inversion recovery MR imaging: Clinical applications and usefulness in a wide spectrum of central nervous system diseases. ( 30016704 )
2019
9
Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. ( 29380517 )
2019
10
α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. ( 29185388 )
2019
11
Differential role of MyD88 signaling in Streptococcus suis serotype 2-induced systemic and central nervous system diseases. ( 30944920 )
2019
12
The associations between central nervous system diseases and haemostatic disorders. ( 30868969 )
2019
13
Significance and Mechanisms of P-glycoprotein in Central Nervous System Diseases. ( 30854958 )
2019
14
Diazaspirononane Inhibitors of O-GlcNAc Hydrolase for the Treatment of Central Nervous System Diseases. ( 30783492 )
2019
15
Structure-Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases. ( 30664830 )
2019
16
Is the Eye an Extension of the Brain in Central Nervous System Disease? ( 28609158 )
2018
17
Production of transgenic pigs using a pGFAP-CreERT2/EGFP LoxP inducible system for central nervous system disease models. ( 29284207 )
2018
18
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. ( 29332716 )
2018
19
A matrix metalloproteinase 9 (MMP9) gene single nucleotide polymorphism is associated with predisposition to tick-borne encephalitis virus-induced severe central nervous system disease. ( 29496490 )
2018
20
Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up. ( 29515419 )
2018
21
Stem cells in the treatment of central nervous system disease. ( 29523970 )
2018
22
Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation. ( 30013417 )
2018
23
Rat Lungworm Infection Associated with Central Nervous System Disease - Eight U.S. States, January 2011-January 2017. ( 30070981 )
2018
24
MicroRNAs of microglia: Wrestling with central nervous system disease. ( 30323123 )
2018
25
Testing for Bartonella ssp. DNA in cerebrospinal fluid of dogs with inflammatory central nervous system disease. ( 30381844 )
2018
26
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease. ( 30537919 )
2018
27
Expression of microRNAs in cerebrospinal fluid of dogs with central nervous system disease. ( 30563542 )
2018
28
Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion. ( 30518982 )
2018
29
The Gut-Microglia Connection: Implications for Central Nervous System Diseases. ( 30344525 )
2018
30
A Review of Stem Cell Therapy for Acquired Brain Injuries and Neurodegenerative Central Nervous System Diseases. ( 30269801 )
2018
31
Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. ( 30175635 )
2018
32
Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases. ( 29998779 )
2018
33
Physiological Roles of Metallothioneins in Central Nervous System Diseases. ( 29962397 )
2018
34
Macrophages as Nanocarriers for Drug Delivery: Novel Therapeutics for Central Nervous System Diseases. ( 29768873 )
2018
35
Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases. ( 29750408 )
2018
36
The Role of IRE1 Signaling in the Central Nervous System Diseases. ( 29663887 )
2018
37
Central nervous system diseases and Scutellaria: a review of current mechanism studies. ( 29554597 )
2018
38
Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. ( 28075486 )
2017
39
Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. ( 28288111 )
2017
40
Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe? ( 28398199 )
2017
41
Occupational exposure to extremely low-frequency magnetic fields and risk for central nervous system disease: an update of a Danish cohort study among utility workers. ( 28429106 )
2017
42
Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. ( 28453910 )
2017
43
Cerebrospinal fluid pleocytosis in infectious and noninfectious central nervous system disease: A retrospective cohort study. ( 28471963 )
2017
44
Central Nervous System Disease, Education, and Race Impact Radiation Refusal in Pediatric Cancer Patients. ( 28538508 )
2017
45
Central nervous system disease in pediatric acute myeloid leukemia. ( 28853216 )
2017
46
Metabolic Profiling of Central Nervous System Disease in Trypanosoma brucei rhodesiense Infection. ( 28927234 )
2017
47
Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii. ( 28933846 )
2017
48
Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. ( 29038655 )
2017
49
Central Nervous System Disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. ( 29061243 )
2017
50
Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. ( 29103429 )
2017

Variations for Central Nervous System Disease

Expression for Central Nervous System Disease

Search GEO for disease gene expression data for Central Nervous System Disease.

Pathways for Central Nervous System Disease

GO Terms for Central Nervous System Disease

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 astrocyte projection GO:0097449 9.16 APP GFAP
2 glial cell projection GO:0097386 8.96 GFAP MAPT
3 main axon GO:0044304 8.62 APP MAPT

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 CCR1 CXCR3 IFNG IL1B MBP
2 cytokine-mediated signaling pathway GO:0019221 9.86 CCR1 IL1B MMP9 NOS2
3 positive regulation of protein phosphorylation GO:0001934 9.73 APP IFNG IL1B MMP9
4 regulation of insulin secretion GO:0050796 9.67 IFNG IL1B NOS2
5 inflammatory response GO:0006954 9.63 CCR1 CXCR3 IL1B PLP1 SERPINA3 TBK1
6 astrocyte development GO:0014002 9.58 GFAP PLP1
7 positive regulation of glial cell proliferation GO:0060252 9.58 GFAP IL1B
8 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.57 IFNG IL1B
9 memory GO:0007613 9.54 BDNF MAPT
10 synapse organization GO:0050808 9.54 APP GRM5 MAPT
11 astrocyte activation GO:0048143 9.52 APP MAPT
12 amyloid fibril formation GO:1990000 9.51 APP MAPT
13 modulation of age-related behavioral decline GO:0090647 9.48 APP GRM5
14 positive regulation of receptor binding GO:1900122 9.46 BDNF MMP9
15 axon ensheathment GO:0008366 9.4 MBP PLP1
16 positive regulation of killing of cells of other organism GO:0051712 9.32 IFNG NOS2
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG IL1B
18 axon development GO:0061564 9.13 GFAP MAPT PLP1
19 negative regulation of gene expression GO:0010629 9.1 APP CCR1 IFNG MAPT NOS2 TBK1

Molecular functions related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of myelin sheath GO:0019911 8.62 MBP PLP1

Sources for Central Nervous System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....